Brought to you by 
AZ pays $100mm up front for rights to Rigel's RA candidate; rights later returned
08 Dec 2015
Executive Summary
AstraZeneca PLC will pay $100mm up front for exclusive worldwide development, manufacturing, and commercialization rights to Rigel's (small molecules for inflammation, autoimmune diseases, and metabolic conditions) fostamatinib (R788), a spleen tyrosine kinase (Syk) inhibitor that has completed Phase II trials for rheumatoid arthritis in patients who have not responded to prior drug therapies.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AZ pays $100mm up front for rights to Rigel's RA candidate; rights later returned
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice